Psilocybin for social connection
Treatments studied
Part of Brain & nervous system, Mental health clinical trials.
This trial tests whether a psychedelic psilocybin session can help people who feel very lonely feel more connected to others. If you are medically healthy and often feel isolated, you may be able to join.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be in good physical health
- You must be able to give your informed consent
- You must feel a high degree of loneliness
- You must be willing to follow all study steps and be available for the full study period
- You cannot have any unstable medical or mental health condition that would make the study unsafe for you
- You cannot be pregnant or breastfeeding
- You cannot have metal in your body or a pacemaker that would prevent an MRI scan
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether psilocybin, a naturally occurring psychedelic compound, can help people with depression who experience anhedonia—a loss of interest or pleasure in activities. Researchers will monitor your brain activity and mood changes over time to see if this treatment is safe and helpful.
This trial tests if psilocybin, a substance found in certain mushrooms, can help people with various mental health symptoms that affect daily life. You would take a single dose in a supervised setting and be monitored for changes in your mood and well-being.
This trial tests whether a single dose of psilocybin can help people with treatment-resistant depression by changing how they focus on themselves. It aims to understand how psilocybin affects brain activity and self-related thinking.
This trial tests if a single dose of psilocybin (a psychedelic drug) can help people with prolonged grief disorder. You'll receive counseling and be observed in a safe setting.
This trial tests if psilocybin, a psychedelic substance, can improve the ability to feel pleasure (anhedonia) in people with depression who are not taking antidepressants. It also includes healthy volunteers as a comparison group.
This trial tests whether very low doses of psilocybin (a psychedelic substance) can help reduce emotional distress in people with a life-limiting illness. If you are receiving palliative care and feeling anxious or depressed, this study might offer a way to explore a new treatment option.
Hear when a new Loneliness trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.